NCT02427750View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Human Influenza
Interventions
BIOLOGICAL

Aggripal®

TIV

Trial Locations (1)

40420000

100, Salvador

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY